hMPV Human Metapneumovirus Infection

Recently, a novel respiratory virus has emerged, raising concerns among healthcare professionals worldwide. Similar to human metapneumovirus (hMPV) and respiratory syncytial virus (RSV), this virus appears to primarily affect the respiratory system, causing a wide range of symptoms that vary in severity.

hMPV Latest Situation

In many countries across the Northern Hemisphere, cases of acute respiratory infections tend to rise during this time of year, driven by seasonal epidemics of respiratory pathogens such as seasonal influenza, avian Influenza, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and mycoplasma pneumoniae. Routine surveillance for acute respiratory infections and respiratory pathogens is conducted in many regions, providing insights into current trends.

According to WHO Currently, in some temperate areas of the Northern Hemisphere, rates of influenza-like illness (ILI) and acute respiratory infection (ARI) have increased in recent weeks, exceeding baseline levels as part of usual seasonal patterns. Seasonal influenza activity is elevated in many countries, while RSV trends vary by region, with detections decreasing in most areas except in North America.

Recently, attention has turned to hMPV, particularly in China, where there are reports of increased respiratory illness and suggestions of hospitals being overwhelmed. hMPV is a common virus that circulates in many countries from winter through spring. Although hMPV infection is usually mild, resembling the common cold, severe cases can lead to bronchitis or pneumonia, requiring hospitalization. However, not all countries routinely test for or publish data on hMPV trends.

In China, surveillance data up to December 29, 2024, indicates a seasonal rise in acute respiratory infections, with increased detections of seasonal influenza, rhinovirus, RSV, and hMPV, particularly in northern provinces. These trends align with expectations for winter in the Northern Hemisphere. Influenza remains the most frequently detected respiratory pathogen in China among patients with acute respiratory infections. Chinese health authorities have reported that the healthcare system is not overwhelmed, and there have been no emergency declarations or significant disruptions.

What is hMPV?

Early reports indicate that the virus can cause mild symptoms such as cough, sore throat, and nasal congestion, resembling a common cold. However, in vulnerable populations such as young children, the elderly, and individuals with compromised immune systems, the infection can progress to severe complications. These include bronchitis, bronchiolitis, and pneumonia, with potential for acute respiratory distress syndrome (ARDS) in critical cases.

Preliminary research suggests that this virus might share similarities in transmission pathways with other respiratory viruses, spreading primarily through respiratory droplets and close contact with infected individuals. Enhanced surveillance and diagnostic tools are essential for early detection and containment of outbreaks.

While no specific antiviral treatments have been established yet, supportive care remains the cornerstone of management. Preventive measures, such as frequent handwashing, wearing masks in crowded places, and vaccination (if available), play a critical role in reducing the spread. As research continues, understanding the characteristics and behavior of this virus will be crucial for developing targeted treatments and public health strategies to mitigate its impact.

History of hMPV

Human metapneumovirus (hMPV) belongs to the Pneumovirinae subfamily of the Paramyxoviridae family, much like respiratory syncytial virus (RSV). Genetically, however, hMPV is most closely related to avian metapneumovirus, previously known as turkey rhinotracheitis virus. Both viruses are classified under the genus Metapneumovirus, with hMPV being the first in this genus identified to cause disease in humans.

It is hypothesized that hMPV originated from birds, suggesting a zoonotic divergence. However, serological evidence indicates that hMPV has been circulating among humans since at least 1958, pointing to its long-standing adaptation to human hosts.

The discovery of hMPV came in 2001, when researchers in the Netherlands identified the virus in stored nasopharyngeal samples from children with respiratory illness. Using reverse transcription-polymerase chain reaction (RT-PCR) techniques, they detected the virus and found its genome shared 88% similarity with avian metapneumovirus serotype C. Notably, hMPV was shown to replicate in monkeys but not in birds, further differentiating it from its avian counterpart.

Since its initial identification, hMPV has been detected across all continents except Antarctica, underscoring its global presence and significance.

Structurally, hMPV is a non-segmented, single-stranded negative-sense RNA virus. It is classified into two antigenically distinct groups, A and B, which are further subdivided into five sublineages based on genetic variations in the G and F genes: A1, A2a, A2b, B1, and B2. This genetic diversity contributes to its ability to cause a wide range of respiratory illnesses across different populations.

Sign and Symptoms of hMPV Infection

Infection with human metapneumovirus (hMPV) presents with a wide range of respiratory symptoms, varying from mild to severe. These symptoms closely resemble those caused by respiratory syncytial virus (RSV) and include:

  • Fever
  • Cough
  • Rhinorrhea (runny nose)
  • Dyspnea (difficulty breathing)
  • Tachypnea (rapid breathing)
  • Chest retraction and wheezing

The most common clinical presentation of hMPV is bronchiolitis, with or without associated pneumonia. Other conditions reported in association with hMPV include:

  • Asthma exacerbation
  • Otitis media (middle ear infection)
  • Pneumonitis
  • Flu-like illness
  • Community-acquired pneumonia
  • Chronic obstructive pulmonary disease (COPD) exacerbation

These symptoms highlight the diverse clinical impact of hMPV, particularly in vulnerable populations such as children, the elderly, and individuals with underlying respiratory conditions.

The clinical spectrum of hMPV infection ranges from mild upper respiratory tract infections (URTIs) to severe lower respiratory tract infections (LRTIs). Severe cases often present with significant wheezing and may progress to life-threatening conditions such as bronchiolitis and pneumonia.

Among pediatric populations, hMPV is a leading cause of LRTIs, second only to respiratory syncytial virus (RSV). Its impact highlights the importance of recognizing and managing this virus in clinical practice to reduce its burden on public health.

Treatment of Human Metapneumovirus (hMPV)

Currently, there is no FDA-approved antiviral therapy specifically for human metapneumovirus (hMPV) infection. Management primarily focuses on supportive care, including symptomatic treatment and respiratory support when necessary.

Investigational and Supportive Therapies:

  1. Ribavirin:
    • Ribavirin, a broad-spectrum antiviral agent, has shown activity against hMPV in laboratory studies.
    • In animal models, such as hMPV-infected cotton rats, ribavirin reduced viral replication in the lungs and decreased pulmonary inflammation.
    • Case reports suggest that oral ribavirin, combined with intravenous immunoglobulins (IVIG), may help improve symptoms in immunosuppressed individuals.
  2. Intravenous Ribavirin:
    • IV ribavirin has been used in immunocompromised adults, but its benefits remain uncertain.

Limitations:

  • The use of ribavirin in hMPV and other viral infections is controversial due to limited evidence from randomized controlled trials.
  • Further research is needed to confirm its efficacy and safety in clinical settings.

In the absence of specific antiviral treatments, supportive care remains the cornerstone of managing hMPV infections, emphasizing the importance of monitoring and addressing respiratory complications.

Frequently Asked Questions (FAQs) about hMPV
What is hMPV?

hMPV is a respiratory virus similar to RSV, causing mild to severe symptoms like cough, fever, and difficulty breathing.

When does hMPV typically circulate?

hMPV commonly circulates from winter to spring in many countries, particularly in the Northern Hemisphere.

Who is at risk of hMPV?

Young children, the elderly, and those with weakened immune systems are most vulnerable to severe complications.

How is hMPV transmitted?

It spreads through respiratory droplets and close contact with infected individuals.

Related posts

Hantavirus Symptoms, Transmission & Prevention 2026

Ozempic and Mental Health: What GLP-1 Drugs Do to Depression, Anxiety and the Brain

Avian Influenza Medication: Treatment Guidelines